Article Sidebar
Views PDF: 0
THE RESULTS OF SURGICAL TREATMENT AND I-131 THERAPY ON PATIENTS WITH PAPILLAR THYROID CANCER AT THE MILITARY INSTITUTE OF RADIOLOGY MEDICINE AND ONCOLOGY
Main Article Content
Abstract
papillary thyroid cancer at the military institute of radiation medicine and oncology. Methods: Prospective, cross-sectional, convenient sample study on 119 patients with papillary thyroid cancer at the Military Institute of Radiation Medicine and Oncology from June 2023 to May 2024. Results: Prognostic factors for incomplete response to I-131 treatment: Tumor with characteristics of invading adjacent organs (at 3 months) with OR = 5.07, 95% CI = 1.22 - 21.03, p < 0.05. Stage III - IV (at 3 months, 6 months) with OR: 5.31 (p < 0.05) and 4.17 (p < 0.05). Group of patients with intermediate and high risk of recurrence after surgery (at 6 months) with OR = 4.08, 95%CI = 1.13-14.73, p < 0.05. Group of I-131 treatment dose > 50 mCi (at 6 months) with OR = 5.89, 95%CI = 1.86-18.71, p < 0.05. High Tg before treatment (> 10 ng/ml) (3 months, 6 months) with OR: 4.10 and 15.18 (p < 0.05). Female gender is a factor that reduces the risk of poor response to I-131 treatment (3 months, 6 months) with OR = 0.21 (p < 0.05) and OR = 0.27 (p < 0.05).
Article Details
Keywords
Papillary Thyroid Microcarcinoma, surgery, I-131 Radiotherapy
References
2. Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022; 33(1):27-63.
3. Bryan R Haugen, Erik K Alexander, Keith C Bible, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan 1; 26(1):1-133.
4. Nguyễn Quốc An, Nguyễn Quang Bảy, Ngô Đức Kỷ. Nhận xét đặc điểm lâm sàng, cận lâm sàng của bệnh nhân ung thư biểu mô tuyến giáp thể nhú được phẫu thuật cắt toàn bộ tuyến giáp và nạo vét hạch cổ. Tạp chí Y học Việt Nam. 2022; 518(1).
5. Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: Our treatment strategies and outcomes. World J Surg. 2010; 34(6):1222-1231.
6. Faro FN, Simões VRF, Ricardo GP, et al. Prognostic factors for incomplete response in thyroid microcarcinoma: An analysis of initial response to therapy in 517 patients. Archives of Endocrinology Metabolism. 2021; 65:579-587.
7. Cao J, Yun C, Zhu X, et al. Clinical analysis of the short-term outcome of papillary thyroid micro carcinoma after (131)I treatment. Cancer Manag Res. 2021; 13:4691-4698.
8. Ben Hamida O, Sellem A, El Ajmi W, et al. Preablative stimulated thyroglobulin in predicting dynamic risk stratification after 1 year in patients with differentiated thyroid cancer. Médecine Nucléaire. 2021; 45(1):46-49.
9. Trần Văn Giang. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị I-131 ở bệnh nhân vi ung thư tuyến giáp thể nhú sau phẫu thuật cắt toàn bộ tuyến giáp. Luận văn Thạc sĩ Y học, Trường Đại học Y Hà Nội. 2022.
10. Park HJ, Jeong GC, Kwon SY, et al. Stimulated serum thyroglobulin level at the time of first dose of radioactive iodine therapy is the most predictive factor for therapeutic failure in patients with papillary thyroid carcinoma. Nuclear medicine molecular imaging. 2014; 48:255-261.